Drug General Information
Drug ID	D08TRG
Former ID	DIB014163
Drug Name	AZD-3241
Synonyms	Parkinson's disease therapeutic, AstraZeneca
Indication	Parkinson's disease [ICD9: 332; ICD10:G20]		Phase 2	[525118]
Company	AstraZeneca plc
Structure		Download 2D MOL 3D MOL
Target and Pathway
Target(s)	Myeloperoxidase	Target Info	Inhibitor	[533278]
KEGG Pathway	Phagosome
	Transcriptional misregulation in cancer
Pathway Interaction Database	C-MYB transcription factor network
	IL23-mediated signaling events
WikiPathways	Folate Metabolism
	Vitamin B12 Metabolism
	Selenium Micronutrient Network
References
Ref 525118	ClinicalTrials.gov (NCT02388295) AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients. U.S. National Institutes of Health.
Ref 533278	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015 Sep;138(Pt 9):2687-700.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.